{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Pancreas&page=10",
    "query": {
      "condition": "Carcinoma, Pancreas",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 2231,
    "total_pages": 224,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Pancreas&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Pancreas&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T13:00:48.717Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00536770",
      "title": "A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "placebo + gemcitabine + erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo + gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "calcitriol + gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "calcitriol + gemcitabine + erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novacea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2007-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-11-06",
      "last_synced_at": "2026-10-15T13:00:48.717Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00536770"
    },
    {
      "nct_id": "NCT00222469",
      "title": "Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2005-08",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2008-07-09",
      "last_synced_at": "2026-10-15T13:00:48.717Z",
      "location_count": 2,
      "location_summary": "Oklahoma City, Oklahoma • Houston, Texas",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00222469"
    },
    {
      "nct_id": "NCT01783171",
      "title": "Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Stage III Pancreatic Cancer AJCC v6 and v7",
        "Stage IV Pancreatic Cancer AJCC v6 and v7",
        "Unresectable Pancreatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Akt Inhibitor MK2206",
          "type": "DRUG"
        },
        {
          "name": "Dinaciclib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2013-01-15",
      "completion_date": "2016-07-12",
      "has_results": false,
      "last_update_posted_date": "2017-08-22",
      "last_synced_at": "2026-10-15T13:00:48.717Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Denver, Colorado • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01783171"
    },
    {
      "nct_id": "NCT04503265",
      "title": "A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "Breast Cancer",
        "Ovarian Cancer",
        "Homologous Recombination Deficiency",
        "Prostate Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "AMXI-5001:Dose Escalation Phase I",
          "type": "DRUG"
        },
        {
          "name": "AMXI-5001:Dose Expansion Phase II",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AtlasMedx, Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2020-08-12",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2025-05-01",
      "last_synced_at": "2026-10-15T13:00:48.717Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04503265"
    },
    {
      "nct_id": "NCT06885424",
      "title": "A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Solid Tumor Cancer",
        "Solid Tumor, Unspecified, Adult",
        "Colorectal Carcinoma",
        "Colorectal Carcinoma (CRC)",
        "Non Small Cell Lung Cancer",
        "Small Cell Lung Cancer ( SCLC )",
        "Pancreatic Cancer",
        "NSCLC",
        "Mesothelioma",
        "Ovarian Cancer",
        "Ovarian Carcinoma",
        "Head and Neck (HNSCC)",
        "Head and Neck Cancer",
        "Renal Cell Carcinoma (Kidney Cancer)",
        "Triple Negative Breast Cancer (TNBC)"
      ],
      "interventions": [
        {
          "name": "No additional intervention administered in this long term follow-up study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "A2 Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2025-07-31",
      "completion_date": "2040-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-10-15T13:00:48.717Z",
      "location_count": 3,
      "location_summary": "Gilbert, Arizona • Rochester, Minnesota • New York, New York",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06885424"
    },
    {
      "nct_id": "NCT00816179",
      "title": "Diagnostic Endoscopic Exploration for Pancreatic Head Mass",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pancreatic Head Mass"
      ],
      "interventions": [
        {
          "name": "Transgastric diagnostic endoscopic peritoneoscopy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Jeffrey Hazey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 11,
      "start_date": "2008-07",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-11-03",
      "last_synced_at": "2026-10-15T13:00:48.717Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00816179"
    },
    {
      "nct_id": "NCT07481383",
      "title": "A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma Non-resectable"
      ],
      "interventions": [
        {
          "name": "ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Continuity Biosciences, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2026-03-11",
      "completion_date": "2027-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-15T13:00:48.717Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Morgantown, West Virginia",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07481383"
    },
    {
      "nct_id": "NCT02843945",
      "title": "Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Directional Brachytherapy Source Implant",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "CivaTech Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2017-05-31",
      "completion_date": "2028-10-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-10-15T13:00:48.717Z",
      "location_count": 6,
      "location_summary": "Tampa, Florida • Chicago, Illinois • Oak Lawn, Illinois + 3 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02843945"
    },
    {
      "nct_id": "NCT05179824",
      "title": "Tempus Priority Study: A Pan-tumor Observational Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Prostate Cancer",
        "Bladder Cancer",
        "Lung Cancer",
        "Brain Cancer",
        "Pancreatic Cancer",
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Cancer of Liver",
        "Cancer of Colon",
        "Cancer of Head and Neck",
        "Cancer of Stomach",
        "Cancer of Gastrointestinal Tract",
        "Cancer of Rectum",
        "Cancer of Esophagus",
        "Cancer of Skin",
        "Cancer of Cervix",
        "Cancer of Kidney",
        "Cancer of Larynx",
        "Cancer of Endometrium",
        "Cancer of the Bile Duct",
        "Cancer of Vulva",
        "Cancer of Bone and Connective Tissue",
        "Leukemia",
        "Lymphoma",
        "Spinal Cord Cancer"
      ],
      "interventions": [
        {
          "name": "Observation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Tempus AI",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2020-10-19",
      "completion_date": "2030-10-19",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-10-15T13:00:48.717Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05179824"
    },
    {
      "nct_id": "NCT02208024",
      "title": "Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2014-08-27",
      "completion_date": "2019-05-12",
      "has_results": true,
      "last_update_posted_date": "2022-04-29",
      "last_synced_at": "2026-10-15T13:00:48.717Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02208024"
    }
  ]
}